Under a new agreement, Spectrum Chemicals is to distribute Angus Chemical’s TRIS Amino AC USP/EP (pictured) and BIS-TRIS biologics-grade buffers to the biopharmaceutical and life sciences industries in the US and Canada. The company said that these complement its own bioprocessing portfolio such as the BioCertified product line.

Angus is the world’s largest and only fully integrated manufacturer of TRIS buffers. These are used as buffering agents in cell culture and bioprocessing applications, and in the purification of biological molecules in downstream processing.

SK Pharmteco has announced a two-phase, $35 million investment to boost both capacity and capabilities at its SK Biotek subsidiary’s manufacturing plant at Swords, Dublin. This is due online in 2024, the campus’s 60th anniversary as a small molecule API manufacture, and will lead to a 50% total increase in capacity.

Piramal Pharma Solutions (PPS) has announced the implementation of “various tools to unlock API manufacturing capacity and support client needs in drug development and on-patent projects” at its 40-hectare site at Digwal in the Indian state of Telangana. This came shortly after its new API plant at Aurora, Ontario, came online.

Private equity firm Aterian Investment Partners has acquired EverZinc and will combine it with existing affiliate US Zinc to make the world’s largest maker of zinc chemical products. This will be based in Houston and will operate under the EverZinc name, with EverZinc CEO Vincent Dujardin becoming CEO and US Zinc president and CEO Joel Hawthorne as vice chairman.

Italian CDMO Olon is to invest €10 million to create an R&D hub at its headquarters site at Rodano near Milan. This will integrate seven existing R&D centres and will be dedicated entirely to research laboratories to be used to develop APIs and manufacturing processes. 

Construction has started and is due to be completed in Q2 2023. This will also lead to about 50 new researchers being hired, bringing the corporate total to around 350.

Hanmi Fine Chemical, an API manufacturing subsidiary of Hanmi Pharmaceutical, has announced plans for a new business offering what it calls ‘high-tech CDMO’ services. It will spend €7.4 million to build facilities for them and expects to form partnerships with more companies in 2H 2022, in addition to the ten it already has.

A little flexibility in approach will improve consistency and enable pharma partners to perform to their optimum level. Ahead of her presentation on ‘How to Build a ‘Framework for Managing Your Outsourcing Partner’ at CPhI North America, we spoke with Stephanie Gaulding, executive director of regulatory compliance at Pharmatech Associates